SSA
GLMD icon

Schonfeld Strategic Advisors’s Galmed Pharmaceuticals GLMD Stock Holding History

Schonfeld Strategic Advisors’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23,194
Closed -$42.7K – 2336
2025
Q2 		$42.7K Sell
23,194
-2,000
-8% -$2.94K ﹤0.01% 1893
2025
Q1 		$36.3K Sell
25,194
-206
-0.8% -$507 ﹤0.01% 2080
2024
Q4 		$81K Buy
+25,400
New +$86K ﹤0.01% 1851
2018
Q3 		– Sell
-278
Closed -$595K – 878
2018
Q2 		$595K Buy
+278
New +$402K 0.03% 500

Other funds holding GLMD

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Schonfeld Strategic Advisors's GLMD Position: Q3 2025 in Review

Schonfeld Strategic Advisors sold out of Galmed Pharmaceuticals (GLMD) in Q3 2025, closing a stake of 23,194 shares — an estimated $42.7K sold.

Schonfeld Strategic Advisors first reported a position in GLMD in Q2 2018 and held it in 4 quarters. The position peaked at $595K in Q2 2018. 14 funds tracked by Wall St. Rank hold GLMD as of Q3 2025.

  • Schonfeld Strategic Advisors reported no remaining Galmed Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 23,194 Galmed Pharmaceuticals shares in Q3 2025, an estimated $42.7K.
  • Schonfeld Strategic Advisors first reported a position in Galmed Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Schonfeld Strategic Advisors's Galmed Pharmaceuticals position peaked at $595K in Q2 2018.
  • 14 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.